Interactive Session:
180. Nightmare Bugs: A Case-Based Symposium
Friday, October 6, 2017: 2:00 PM-3:30 PM
Room: 20ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the clinical and therapuetic approach of infections caused by multidrug-resistant organisms
  • review the clinical relevant data supporting the use of new antimicrobials against infections caused by multi-drug resistant organisms
  • assess and appraise the pre-clinical evidence available for the selction of particular antimicrobials when a clinican is faced with a challenging infection to treat.
  • list relevant mechanisms of antimicrobial resistance and put them in a clinical context

Target Audience: Academicians, Clinicians, Fellows, Healthcare workers, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Researchers, Scientists

Tracks: Trainee, Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Robert A. Bonomo, MD, Case Western Reserve University , David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health and Cesar Arias, MD, PhD, FIDSA, University of Texas McGovern School of Medicine

Interactive Panelists:  Lilian M. Abbo, MD, University of Miami-Jackson Health System , Dimitrios Farmakiotis, MD, FACP, Warren Alpert Medical School of Brown University , Roy Chemaly, MD, MPH, MD Anderson Cancer Center and Catherine Liu, MD, FIDSA, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-284-L01-P


R. A. Bonomo, Entasis: Grant Investigator , Research grant
Allecra: Grant Investigator , Research grant
Wockhardt: Grant Investigator , Research grant
Merck: Grant Investigator , Research grant
Roche: Grant Investigator , Research grant
GSK: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Shionogi: Grant Investigator , Research grant

D. R. Andes, Cidara: Grant Investigator , Research support
Paratek: Grant Investigator , Research support

C. Arias, The Medecins Company: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Merck: Grant Investigator , Grant recipient

L. M. Abbo, None

D. Farmakiotis, Astellas Pharma: Trial Site PI , Research support

R. Chemaly, Merck: Consultant , Grant Investigator and Investigator , Consulting fee , Grant recipient and Research grant
Chimerix: Consultant and Investigator , Consulting fee and Research grant
Astellas: Consultant , Consulting fee
Shire: Investigator , Research grant
Novartis: Investigator , Research grant
Oxford Immunotec: Consultant , Consulting fee

C. Liu, Theravance: Independent Efficacy Adjudication Committee , Consulting fee

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.